Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS

Biogen Idec will present 58 data sets from the company’s multiple sclerosis (MS) clinical portfolio of approved and investigational products at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, 2–5 October.

The collection of data being presented at ECTRIMS represents Biogen Idec’s industry-leading expertise in MS research and showcases the company’s deep understanding of differing patient needs. Through decades of cutting-edge science, Biogen Idec has more experience than any other company in advancing the treatment of this disease, recognising that physicians need therapeutic choices to meet treatment goals.

“Biogen Idec is proud to be at the forefront of innovation in MS, which has been made possible through our research and development efforts during the past 30 years,” said Douglas E. Williams, PhD, executive vice president, Research and Development at Biogen Idec. “Our commitment has enabled us to bring a number of therapy options to patients, and we are excited to be presenting data on some promising candidates which have the potential to broaden the treatment spectrum for people living with this chronic, debilitating disease.”